Bio-Techne opens new GMP facility in Bristol to boost cell therapy manufacturing capacity.

Bio-Techne Corporation has launched a new GMP-grade small molecule manufacturing facility in Bristol, UK, enhancing its global infrastructure for cell therapy production. This 10,000-square-foot site features advanced cleanrooms designed to meet strict manufacturing standards, supporting scalable and reproducible processes from early development to commercialization. The expansion complements Bio-Techne's existing operations in the US and strengthens its ability to provide high-quality materials and integrated services to cell therapy developers worldwide. This move addresses industry demands for consistent, scalable manufacturing to accelerate the delivery of transformative therapies to patients.

Bio-Techne's shares are trading at USD 72.52 on Pluang as of Oct 08, 2026 19:12 WIB, showing a minimal 0.02% decline over the past day. The company holds a market capitalization of $11.37 billion, reflecting its significant presence in the health sector. Investor interest remains strong with 100% buy orders recorded on Pluang at this time.